Clinical trials: active, sponsored by West China Hospital
Radiotherapy-induced Oral Mucositis
Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.
Evaluate the effectiveness and safety of traditional Chinese medicine compound in improving radiotherapy-induced oral mucositis in patients with head and neck malignant tumors.
- Trial name
- NCT07339774
- Testing
- Zishui Daohuo oral liquid combined with Kujiu mouthwash, Radiotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- West China Hospital
Resectable Hepatocellular Carcinoma (HCC)
Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death globally. Surgical resection is the mainstay of curative-intent treatment, but the 5-year postoperative recurrence rate can be as high as 70%.
- Trial name
- IMPACT (NCT07912853)
- Testing
- Resection
- Where
- China
- Volunteers
- 380 people
- Sponsor
- West China Hospital
Radiation-induced Dermatitis
Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer
To evaluate the efficacy and safety of superoxide dismutase skin spray for the reducing the acute radiation dermatitis in patients with head and neck malignancies undergoing radiotherapy.
- Trial name
- NCT07704372
- Testing
- A topical superoxide dismutase skin spray
- Where
- China
- Volunteers
- 140 people
- Sponsor
- West China Hospital
Colo-rectal Cancer
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer
P (Population): Patients with advanced colorectal cancer who have failed at least two prior lines of therapy. I (Intervention): Radiotherapy, immunotherapy, and fruquintinib.
- Trial name
- PRIM-CRC3 (NCT07904130)
- Testing
- Personalized ultrafractionated stereotactic adaptive radiotherapy, Immunotherapy, Target Therapy
- Volunteers
- 32 people
- Sponsor
- West China Hospital
Non-small Cell Lung Cancer (NSCLC)
A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC
This is a randomized, multicenter, phase III clinical study to compare the efficacy and safety of perioperative treatment with adebrelimab plus platinum-based chemotherapy versus adebrelimab adjuvant therapy in patients with…
- Trial name
- NCT07895238
- Testing
- Adebrelimab (SHR-1316) + chemotherapy, Adebrelimab
- Volunteers
- 1,088 people
- Sponsor
- West China Hospital
Colorectal Cancer
Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal Cancer
Colorectal cancer (CRC) is among the most common malignancies in China, and approximately half of all patients develop liver metastases.
- Trial name
- NCT07885384
- Testing
- Fruquintinib Combined With Capecitabine, Follow-up observation
- Volunteers
- 140 people
- Sponsor
- West China Hospital
Circumferential Female Urethral Diverticulum
Transvaginal Diverticulum Wall Filling and Coverage Technique for Treating Female Circumferential Urethral Diverticulum
The goal of this clinical study is to learn if a new surgical technique called transvaginal diverticular wall filling and covering is effective and safe for treating circumferential urethral diverticulum (UD) in female patients.
- Trial name
- NCT07006753
- Testing
- Transvaginal Diverticulum Wall Filling and Coverage Technique, Conventional surgery
- Where
- China
- Volunteers
- 100 people
- Sponsor
- West China Hospital
Liver Cancer
PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy
- Trial name
- NCT07053072
- Testing
- Low Dose PD-1 mRNA LNP Vaccine, High dose PD-1 mRNA LNP vaccines
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma
Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Some people with HCC have no visible active tumor on imaging after receiving anticancer treatment.
- Trial name
- SWITCH-R (NCT07866612)
- Testing
- Curative-Intent Liver Resection, Immunotherapy-Based Systemic Maintenance Therapy
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Coronary, Coronary Artery Disease
CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS
The CAPRA-EVO trial is a single-center, randomized, open-label study with blinded endpoint assessment comparing early evolocumab plus standard lipid-lowering therapy versus standard-of-care lipid-lowering therapy in patients with…
- Trial name
- CAPRA-EVO (NCT07612774)
- Testing
- Evolocumab, Serial photon-counting coronary computed tomography angiography, Standard Lipid-Lowering Therapy
- Where
- 2 sites in China
- Volunteers
- 232 people
- Sponsor
- West China Hospital
HCC - Hepatocellular Carcinoma, Watch & Wait
Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
The "Surgery versus Maintenance after Conversion-therapy-achieved Complete/Partial Response in Hepatocellular Carcinoma (SWITCH)" study is a multicenter, open-label, prospective non-randomized cohort study with the protocol…
- Conditions
- HCC - Hepatocellular Carcinoma, Watch & Wait, Surgery
- Trial name
- SWITCH (NCT07410715)
- Testing
- Surgical Resection, Maintenance Therapy Group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- West China Hospital
Carcinoma, Non-Small-Cell Lung (NSCLC)
Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer
Neoadjuvant chemoimmunotherapy has improved outcomes in patients with resectable non-small cell lung cancer (NSCLC), but a substantial proportion of patients do not achieve a major pathological response.
- Trial name
- NEOCTATC (NCT07855965)
- Testing
- Cryo-Thermal Ablation, Toripalimab, Platinum-based doublet chemotherapy
- Where
- 9 sites in China
- Volunteers
- 40 people
- Sponsor
- West China Hospital
TNBC - Triple-Negative Breast Cancer
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
Triple-negative breast cancer (TNBC) presents significant challenges due to its limited treatment options and poor efficacy. While neoadjuvant chemotherapy has improved breast-conserving rates and extended survival for TNBC…
- Trial name
- NCT06627712
- Testing
- SBRT+PD-1 Inhibitor + Chemotherapy, PD-1 Inhibitor + Chemotherapy
- Where
- China
- Volunteers
- 318 people
- Sponsor
- West China Hospital
Kaposiform Hemangioendothelioma
Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of…
- Trial name
- NCT07131644
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 120 people
- Sponsor
- West China Hospital
Calcific Aortic Valve Disease, AORTIC VALVE DISEASES
Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression
Calcific aortic valve stenosis (CAVS) is a condition in which the aortic valve progressively narrows and stiffens due to calcium deposition, eventually impairing blood flow from the heart to the body.
- Conditions
- Calcific Aortic Valve Disease, AORTIC VALVE DISEASES, Aortic Valve Stenosis
- Trial name
- VERIFICATION (NCT07715279)
- Testing
- Vericiguat (BAY1021189)
- Where
- China
- Volunteers
- 238 people
- Sponsor
- West China Hospital
Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
The purpose of this study is to evaluate the efficacy and safety of a short-term (12-week) prehabilitation strategy combining mazdutide (a novel GLP-1/GCG receptor dual agonist) with lifestyle optimization, compared to lifestyle…
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors
- Trial name
- PRIME (NCT07718126)
- Testing
- Mazdutide, Lifestyle Optimization
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma
This study is evaluating the safety and potential effectiveness of adding folic acid to atezolizumab plus bevacizumab as first-line treatment for adults with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT07835737
- Testing
- Folic Acid, Atezolizumab & Bevacizumab
- Volunteers
- 78 people
- Sponsor
- West China Hospital
HPV-positive Oropharyngeal Squamous Cell Carcinoma
Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC
This phase I, open-label, single-arm trial uses a "3+3" dose-escalation design to evaluate the safety, tolerability, and preliminary efffcacy of intranasal WSK-IM05 vaccine combined with tislelizumab as neoadjuvant therapy in…
- Trial name
- NCT07565740
- Testing
- WSK-IM05 (4×10^10 vp), WSK-IM05 (8×10^10 vp), WSK-IM05 (1.6x10^11 vp)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Infantile Hemangioma
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma
The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).
- Trial name
- NCT06798363
- Testing
- propranolol
- Where
- 3 sites in China
- Volunteers
- 32 people
- Sponsor
- West China Hospital
Advanced Melanoma
Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy
Advanced melanoma is a highly aggressive malignancy that frequently exhibits resistance to conventional radiotherapy and single-agent immunotherapy.
- Trial name
- NCT07562841
- Testing
- Au-TMP, Fractionated Radiotherapy (RT), Toripalimab
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- West China Hospital